drugset / Trial / NCT00492141

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

NCT00492141

Phase 1/2 Completed 10 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objectives: 1. To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. 2. To determine the effectiveness of L9-NC given by aerosol in combination with temozolomide in patients with solid tumors involving the lungs.

Timeline

Start
2006-06
Primary completion
2007-05
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 100 mg/m2 Oral
Subject rubitecan Unknown 0.4 mg/ml Inhaled

Indications